Citations (165)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Zonglin Li, Chu Lin, Jinyu Zhou, Xiaoling Cai, Xingyun Zhu, Suiyuan Hu, Fang Lv, Wenjia Yang & Linong Ji. (2022) Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants. Expert Opinion on Investigational Drugs 31:9, pages 957-964.
Read now
Read now
Jaquellyne Gurgel Penaforte-Saboia, Carlos Eduardo Barra Couri, Natasha Vasconcelos Albuquerque, Vanessa Lauanna Lima Silva, Natália Bitar da Cunha Olegario, Virgínia Oliveira Fernandes & Renan Magalhães Montenegro Junior. (2021) Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity 14, pages 565-573.
Read now
Read now
Zhong Yuan, Frank DeFalco, Lu Wang, Laura Hester, James Weaver, Joel N. Swerdel, Amy Freedman, Patrick Ryan, Martijn Schuemie, Rose Qiu, Jacqueline Yee, Gary Meininger, Jesse A. Berlin & Norman Rosenthal. (2020) Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Current Medical Research and Opinion 36:7, pages 1117-1124.
Read now
Read now
Xueying Tan & Jingbo Hu. (2016) Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 17:9, pages 1285-1293.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Yoshifumi Saisho. (2015) Alogliptin benzoate for management of type 2 diabetes. Vascular Health and Risk Management 11, pages 229-243.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Agostino Consoli & Gloria Formoso. (2015) Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opinion on Drug Safety 14:2, pages 207-218.
Read now
Read now
Chin-Hsiao Tseng, Kuo-Yang Lee & Farn-Hsuan Tseng. (2015) An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C 33:1, pages 67-124.
Read now
Read now
Jocelyn de Heer & Burkhard Göke. (2014) Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?. Expert Opinion on Drug Safety 13:11, pages 1469-1481.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Karoline von Websky, Christoph Reichetzeder & Berthold Hocher. (2013) Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. Vascular Health and Risk Management 9, pages 681-694.
Read now
Read now
Qiang Du, Bo Wu, Yan-Jun Wang, Sheng Yang, Yue-Yang Zhao & Yuan-yuan Liang. (2013) Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Current Medical Research and Opinion 29:11, pages 1487-1494.
Read now
Read now
Carolyn F Deacon & Jens J Holst. (2013) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy 14:15, pages 2047-2058.
Read now
Read now
Andre Scheen. (2013) Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opinion on Drug Safety 12:4, pages 545-557.
Read now
Read now
Avivit Cahn & Itamar Raz. (2013) Emerging gliptins for type 2 diabetes. Expert Opinion on Emerging Drugs 18:2, pages 245-258.
Read now
Read now
Shamsa Ali & Vivian Fonseca. (2013)
Saxagliptin overview: special focus on safety and adverse effects. Expert Opinion on Drug Safety 12:1, pages 103-109.
Read now
Read now
Lene Hoimark, Torben Laursen & Jørgen Rungby. (2012) Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 5, pages 295-302.
Read now
Read now
Robert M. Guthrie. (2012) Evolving Therapeutic Options for Type 2 Diabetes Mellitus: An Overview. Postgraduate Medicine 124:6, pages 82-89.
Read now
Read now
Jennifer B. Green. (2012) The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety. Postgraduate Medicine 124:4, pages 54-61.
Read now
Read now
Edoardo Mannucci & Ilaria Dicembrini. (2012) Incretin-based therapies and cardiovascular risk. Current Medical Research and Opinion 28:5, pages 715-721.
Read now
Read now
Carolyn F Deacon & Nikolaus Marx. (2012) Potential cardiovascular effects of incretin-based therapies. Expert Review of Cardiovascular Therapy 10:3, pages 337-351.
Read now
Read now
Articles from other publishers (143)
Lin Zhang, Wei Mao, Dan Liu, Bin Hu, Xiaofang Lin, Jie Ran, Xingxing Li & Jing Hu. (2023) Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS). Frontiers in Pharmacology 14.
Crossref
Crossref
Ali A. Aghdassi, Mats L. Wiese, Quang Trung Tran & Markus M. Lerch. 2023. The Pancreas. The Pancreas
199
207
.
Federico Bernardini, Annunziata Nusca, Federica Coletti, Ylenia La Porta, Mariagrazia Piscione, Francesca Vespasiano, Fabio Mangiacapra, Elisabetta Ricottini, Rosetta Melfi, Ilaria Cavallari, Gian Paolo Ussia & Francesco Grigioni. (2023) Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease. Pharmaceutics 15:7, pages 1858.
Crossref
Crossref
Ruping Pan, Jiadai Liu & Yong Chen. (2023) Treatment of obesity-related diabetes: significance of thermogenic adipose tissue and targetable receptors. Frontiers in Pharmacology 14.
Crossref
Crossref
Rexiati Ruze, Yuan Chen, Ruiyuan Xu, Jianlu Song, Xinpeng Yin, Chengcheng Wang & Qiang Xu. (2023) Obesity, diabetes mellitus, and pancreatic carcinogenesis: Correlations, prevention, and diagnostic implications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:1, pages 188844.
Crossref
Crossref
Kozo Okada, Shinnosuke Kikuchi, Shotaro Kuji, Naoki Nakayama, Nobuhiko Maejima, Yasushi Matsuzawa, Noriaki Iwahashi, Masami Kosuge, Toshiaki Ebina, Kazuo Kimura, Kouichi Tamura & Kiyoshi Hibi. (2022) Impact of early intervention with alogliptin on coronary plaque regression and stabilization in patients with acute coronary syndromes. Atherosclerosis 360, pages 1-7.
Crossref
Crossref
Tingting Liang, Xinqiang Xie, Lei Wu, Longyan Li, Lingshuang Yang, He Gao, Zhenshan Deng, Xiangqian Zhang, Xuefeng Chen, Jumei Zhang, Yu Ding & Qingping Wu. (2022) Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis. Frontiers in Nutrition 9.
Crossref
Crossref
Janaka Karalliedde, Peter Winocour, Tahseen A. Chowdhury, Parijat De, Andrew H. Frankel, Rosa M. Montero, Ana Pokrajac, Debasish Banerjee, Indranil Dasgupta, Damian Fogarty, Adnan Sharif, Mona Wahba, Patrick B. Mark, Sagen Zac‐Varghese, Dipesh C. Patel & Stephen C. Bain. (2022) Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Diabetic Medicine 39:4.
Crossref
Crossref
Georg Beyer, Albrecht Hoffmeister, Patrick Michl, Thomas Mathias Gress, Wolfgang Huber, Hana Algül, Albrecht Neesse, Alexander Meining, Thomas W. Seufferlein, Jonas Rosendahl, Stefan Kahl, Jutta Keller, Jens Werner, Helmut Friess, Philip Bufler, Matthias J. Löhr, Alexander Schneider, Petra Lynen Jansen, Irene Esposito, Lars Grenacher, Joachim Mössner, Markus M. Lerch & Julia Mayerle. (2022) S3-Leitlinie Pankreatitis – Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – September 2021 – AWMF Registernummer 021-003. Zeitschrift für Gastroenterologie 60:03, pages 419-521.
Crossref
Crossref
Qutuba G Karwi, Kim L Ho, Simran Pherwani, Ezra B Ketema, Qiuyu Sun & Gary D Lopaschuk. (2022) Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. Cardiovascular Research 118:3, pages 686-715.
Crossref
Crossref
Alessia Maria Calabrese, Valeria Calsolaro, Sara Rogani, Chukwuma Okoye, Nadia Caraccio & Fabio Monzani. (2021) Optimal Type 2 Diabetes Mellitus Management and Active Ageing. Endocrines 2:4, pages 523-539.
Crossref
Crossref
Fu-Shun Yen, James Cheng-Chung Wei, Hei-Tung Yip, Chii-Min Hwu, Ming-Chih Hou & Chih-Cheng Hsu. (2021) Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan. Hepatology International 15:1, pages 179-190.
Crossref
Crossref
Tatsuya Minami, Ryosuke Tateishi, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Masashi Izumiya, Kazuyuki Hanajiri, Yoshinari Asaoka, Yuji Kondo, Yasuo Tanaka, Motoyuki Otsuka, Takamasa Ohki, Masahiro Arai, Atsushi Tanaka, Kiyomi Yasuda, Hideaki Miura, Itsuro Ogata, Toshiro Kamoshida, Kazuaki Inoue, Yukihiro Koike, Masatoshi Akamatsu, Hiroshi Mitsui, Hajime Fujie, Keiji Ogura, Hideo Yoshida, Tomonori Wada, Kiyohiko Kurai, Hisato Maekawa, Shuntaro Obi, Takuma Teratani, Naohiko Masaki, Kayo Nagashima, Takashi Ishikawa, Naoya Kato, Kyoji Moriya, Hiroshi Yotsuyanagi & Kazuhiko Koike. (2021) Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Liver Cancer 10:4, pages 309-319.
Crossref
Crossref
Sushrima GanAdem Y. Dawed, Louise A. DonnellyAnand T.N. NairColin N.A. PalmerViswanathan Mohan & Ewan R. Pearson. (2020) Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 43:8, pages 1948-1957.
Crossref
Crossref
Melanie J. Davies, Cristina Bianchi & Stefano Del Prato. (2020) Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism 107, pages 154242.
Crossref
Crossref
Ilaria Dicembrini, Besmir Nreu, Chiara Montereggi, Edoardo Mannucci & Matteo Monami. (2020) Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetologica 57:6, pages 689-696.
Crossref
Crossref
Dianna Wolfe, Salmaan Kanji, Fatemeh Yazdi, Pauline Barbeau, Danielle Rice, Andrew Beck, Claire Butler, Leila Esmaeilisaraji, Becky Skidmore, David Moher & Brian Hutton. (2020) Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations. PLOS ONE 15:4, pages e0231883.
Crossref
Crossref
Ilaria Dicembrini, Chiara Montereggi, Besmir Nreu, Edoardo Mannucci & Matteo Monami. (2020) Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice 159, pages 107981.
Crossref
Crossref
Zachary T. Bloomgarden. (2019) Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today. Diabetes Research and Clinical Practice 157, pages 107906.
Crossref
Crossref
Sonja Wurm & Walter Spindelböck. (2019) Medikamentös induzierte akute PankreatitisDrug-induced Acute Pancreatitis. Journal für Gastroenterologische und Hepatologische Erkrankungen 17:4, pages 101-107.
Crossref
Crossref
Vishal Kulkarni, BJ Srinivasa, PK Kiran, Vinu Sarathy, S Shivakumar Swamy & Radheshyam Naik. (2021) Acute Pancreatitis Caused by Pemetrexed, Carboplatin, and Gemcitabine in a Patient with Lung Cancer: A Rare Case Report. Indian Journal of Medical and Paediatric Oncology 40:S 01, pages S133-S135.
Crossref
Crossref
Julia Rogal, Aline Zbinden, Katja Schenke-Layland & Peter Loskill. (2019) Stem-cell based organ-on-a-chip models for diabetes research. Advanced Drug Delivery Reviews 140, pages 101-128.
Crossref
Crossref
Angelo Cignarelli, Valentina Annamaria Genchi, Irene Caruso, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola & Francesco Giorgino. (2018) Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’. Diabetes Research and Clinical Practice 143, pages 378-388.
Crossref
Crossref
N.H. Kim, J. Choi, N.H. Kim, K.M. Choi, S.H. Baik, J. Lee & S.G. Kim. (2018) Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study. Diabetes & Metabolism 44:4, pages 361-367.
Crossref
Crossref
Angelo Avogaro & Gian Paolo Fadini. (2018) The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. British Journal of Clinical Pharmacology 84:8, pages 1686-1695.
Crossref
Crossref
Vladimer Darsalia, Thomas Klein, Thomas Nyström & Cesare Patrone. (2018) Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology 136, pages 280-286.
Crossref
Crossref
Fu-Shun Yen, Jen-Huai Chiang, Chun-Wei Pan, Boniface J. Lin, James Cheng-Chung Wei & Chih-Cheng Hsu. (2018) Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. Diabetes Research and Clinical Practice 140, pages 279-287.
Crossref
Crossref
Tesfaye Biftu. 2018. Successful Drug Discovery. Successful Drug Discovery
291
317
.
Ali A. Aghdassi & Markus M. Lerch. 2018. The Pancreas. The Pancreas
230
237
.
Hiroshi Noto. 2018. Diabetes and Aging-related Complications. Diabetes and Aging-related Complications
113
126
.
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
527
569
.
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
44
.
N. A. Petunina, E. V. Goncharova & S. A. Potapova. (2017) CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Medical Council:3, pages 32-37.
Crossref
Crossref
Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar & Wei-Chun Huang. (2017) The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Shih-Wei Lai, Kuan-Fu Liao, Cheng-Li Lin & Hsien-Feng Lin. (2017) Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study. Frontiers in Pharmacology 8.
Crossref
Crossref
Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang & Shizhong Bu. (2017) Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Scientific Reports 7:1.
Crossref
Crossref
Vincent Lo Re, Dena M Carbonari, M Elle Saine, Craig W Newcomb, Jason A Roy, Qing Liu, Qufei Wu, Serena Cardillo, Kevin Haynes, Stephen E Kimmel, Peter P Reese, David J Margolis, Andrea J Apter, K Rajender Reddy, Sean Hennessy, Harshvinder Bhullar, Arlene M Gallagher, Daina B Esposito & Brian L Strom. (2017) Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Research & Care 5:1, pages e000400.
Crossref
Crossref
Lesley J. Scott. (2017) Sitagliptin: A Review in Type 2 Diabetes. Drugs 77:2, pages 209-224.
Crossref
Crossref
Edoardo Mannucci & Matteo Monami. (2016) Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in Therapy 34:1, pages 1-40.
Crossref
Crossref
Han Chen, Xiaoying Zhou, Tao Chen, Bingtuan Liu, Wujuan Jin, Huiyuan Gu, Tianyuan Hong & Guoxin Zhang. (2016) Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Diabetes Therapy 7:4, pages 725-742.
Crossref
Crossref
Helene Bihan, Winda L. Ng, Dianna J. Magliano & Jonathan E. Shaw. (2016) Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Diabetes Research and Clinical Practice 121, pages 27-34.
Crossref
Crossref
Xueying Tan. (2016) Omarigliptin for the treatment of type 2 diabetes. Endocrine 54:1, pages 24-31.
Crossref
Crossref
Masayuki Kaneko & Mamoru Narukawa. (2016) Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 116, pages 171-182.
Crossref
Crossref
Yuichi J. Shimada, Christopher P. Cannon, Yuyin Liu, Craig Wilson, Stuart Kupfer, Venu Menon, William C. Cushman, Cyrus R. Mehta, George L. Bakris, Faeiz Zannad & William B. White. (2016) Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. American Heart Journal 175, pages 18-27.
Crossref
Crossref
Enzo Bonora & Massimo Cigolini. (2016) DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. Nutrition, Metabolism and Cardiovascular Diseases 26:4, pages 273-284.
Crossref
Crossref
Avivit Cahn, Simona Cernea & Itamar Raz. (2016) Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Reviews in Endocrine and Metabolic Disorders 17:1, pages 117-127.
Crossref
Crossref
Chin‐Hsiao Tseng. (2015) Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. European Journal of Clinical Investigation 46:1, pages 70-79.
Crossref
Crossref
Liberata Sportiello, Concetta Rafaniello, Cristina Scavone, Cristiana Vitale, Francesco Rossi & Annalisa Capuano. (2016) The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. International Journal of Cardiology 202, pages 731-735.
Crossref
Crossref
Carolyn F Deacon. 2016. Handbook of Incretin-based Therapies in Type 2 Diabetes. Handbook of Incretin-based Therapies in Type 2 Diabetes
45
60
.
Per-Henrik Groop, Mark E Cooper, Vlado Perkovic, Kumar Sharma, Guntram Schernthaner, Masakazu Haneda, Berthold Hocher, Maud Gordat, Jessica Cescutti, Hans-Juergen Woerle & Maximilian von Eynatten. (2015)
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D
™
trial
. Diabetes and Vascular Disease Research 12:6, pages 455-462.
Crossref
Crossref
Hiroshi Noto, Atsushi Goto, Tetsuro Tsujimoto & Mitsuhiko Noda. (2015) Emerging Link between Diabetes and Cancer. Journal of General and Family Medicine 16:3, pages 170-176.
Crossref
Crossref
Tejas P. Singh, Venkat N. Vangaveti & Usman H. Malabu. (2015) Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis—A review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 9:4, pages 223-229.
Crossref
Crossref
Sohita Dhillon. (2015) Saxagliptin: A Review in Type 2 Diabetes. Drugs 75:15, pages 1783-1796.
Crossref
Crossref
S. Wurm, F. Schreiber & W. Spindelboeck. (2015) Mefenamic acid: A possible cause of drug-induced acute pancreatitis. Pancreatology 15:5, pages 570-572.
Crossref
Crossref
B.A. Kappel, N. Marx & M. Federici. (2015) Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. Nutrition, Metabolism and Cardiovascular Diseases 25:8, pages 697-705.
Crossref
Crossref
Barbara E. Stähli, Catherine Gebhard & Jean-Claude Tardif. (2015) Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications. Current Cardiology Reports 17:7.
Crossref
Crossref
Lang Wu, Jingjing Zhu, Larry J. Prokop & Mohammad Hassan Murad. (2015) Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Scientific Reports 5:1.
Crossref
Crossref
Lawrence A. Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K.M. Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich, Francois Bonnici, Benjamin M. Scirica, Deepak L. Bhatt & Itamar Raz. (2015) Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care 38:6, pages 1145-1153.
Crossref
Crossref
Troels M. JensenKishore Saha & William M. Steinberg. (2015) Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials. Diabetes Care 38:6, pages 1058-1066.
Crossref
Crossref
Jong-Mi Seong, Nam-Kyong Choi, Ju-Young Shin, Yoosoo Chang, Ye-Jee Kim, Joongyub Lee, Ju-Young Kim & Byung-Joo Park. (2015) Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study. PLOS ONE 10:5, pages e0124287.
Crossref
Crossref
Vladimer Darsalia, Martin Larsson, David Nathanson, Thomas Klein, Thomas Nyström & Cesare Patrone. (2015) Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke. Journal of Cerebral Blood Flow & Metabolism 35:5, pages 718-723.
Crossref
Crossref
Davide Soranna, Cristina Bosetti, Manuela Casula, Elena Tragni, Alberico L. Catapano, Carlo La Vecchia, Luca Merlino & Giovanni Corrao. (2015) Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database. Diabetes Research and Clinical Practice 108:2, pages 243-249.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Seiji Sato, Yoshifumi Saisho, Kinsei Kou, Shu Meguro, Masami Tanaka, Junichiro Irie, Toshihide Kawai & Hiroshi Itoh. (2015) Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial. PLOS ONE 10:3, pages e0121988.
Crossref
Crossref
M. Buysschaert, D. Amoussou-Guenou, D. Yanogo & F. Djrolo. (2015) Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015. Médecine des Maladies Métaboliques 9:2, pages 158-163.
Crossref
Crossref
Jang Won SonSungrae Kim. (2015) Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes & Metabolism Journal 39:5, pages 373.
Crossref
Crossref
Mitsuhiko Noda, Atsushi Goto & Hiroshi Noto. (2015) 2) Diabetes and Its Treatment and Cancer. Nihon Naika Gakkai Zasshi 104:9, pages 1897-1900.
Crossref
Crossref
Rebecca Klippstein & David Pozo. 2015. Protein and Peptide Nanoparticles for Drug Delivery. Protein and Peptide Nanoparticles for Drug Delivery
145
168
.
Toshiyuki Hibuse, Norikazu Maeda, Ken Kishida, Takekazu Kimura, Tomoko Minami, Eriko Takeshita, Ayumu Hirata, Yasuhiko Nakagawa, Susumu Kashine, Akemi Oka, Masumi Hayashi, Hitoshi Nishizawa, Tohru Funahashi & Iichiro Shimomura. (2014) A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study. Cardiovascular Diabetology 13:1.
Crossref
Crossref
Sophie J Clarke, Liam M McCormick & David P Dutka. (2014) Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovascular Diabetology 13:1.
Crossref
Crossref
Luis Salvador-Carulla, Ana Fernandez, Rosamond Madden, Sue Lukersmith, Ruth Colagiuri, Ghazal Torkfar & Joachim Sturmberg. (2014) Framing of scientific knowledge as a new category of health care research. Journal of Evaluation in Clinical Practice 20:6, pages 1045-1055.
Crossref
Crossref
S. Halimi & B. Vergès. (2014) Adverse effects and safety of SGLT-2 inhibitors. Diabetes & Metabolism 40:6, pages S28-S34.
Crossref
Crossref
Stefan Z Lutz, Harald Staiger, Andreas Fritsche & Hans-Ulrich Häring. (2014) Antihyperglycaemic therapies and cancer risk. Diabetes and Vascular Disease Research 11:6, pages 371-389.
Crossref
Crossref
Baptist Gallwitz. (2014) Extra-pancreatic effects of incretin-based therapies. Endocrine 47:2, pages 360-371.
Crossref
Crossref
Tetsuhiro Tanaka, Yoshiki Higashijima, Takehiko Wada & Masaomi Nangaku. (2014) The potential for renoprotection with incretin-based drugs. Kidney International 86:4, pages 701-711.
Crossref
Crossref
Guillermo E. Umpierrez & Stanley Schwartz. (2014) Use Of Incretin-Based Therapy in Hospitalized Patients with Hyperglycemia. Endocrine Practice 20:9, pages 933-944.
Crossref
Crossref
H. Zhao, L. Wang, R. Wei, D. Xiu, M. Tao, J. Ke, Y. Liu, J. Yang & T. Hong. (2014) Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes, Obesity and Metabolism 16:9, pages 850-860.
Crossref
Crossref
S. Halimi. (2014) Cancers du pancr?as et s?curit? des incr?tines : ?tat des lieux en 2014. M?decine des Maladies M?taboliques 8:4, pages 380-391.
Crossref
Crossref
Vladimer Darsalia, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm & Cesare Patrone. (2014) GLP-1R activation for the treatment of stroke: Updating and future perspectives. Reviews in Endocrine and Metabolic Disorders 15:3, pages 233-242.
Crossref
Crossref
Angeles Mondragon, Daniel Davidsson, Styliana Kyriakoudi, Annika Bertling, Rosa Gomes-Faria, Patrizia Cohen, Stephen Rothery, Pauline Chabosseau, Guy A. Rutter & Gabriela da Silva Xavier. (2014) Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia. PLoS ONE 9:8, pages e104873.
Crossref
Crossref
Carlos E. Mendez & Guillermo E. Umpierrez. (2014) Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. Diabetes Spectrum 27:3, pages 180-188.
Crossref
Crossref
J. Seufert & B. Gallwitz. (2014) The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes, Obesity and Metabolism 16:8, pages 673-688.
Crossref
Crossref
Hejun Zhao, Rui Wei, Liang Wang, Qing Tian, Ming Tao, Jing Ke, Ye Liu, Wenfang Hou, Lin Zhang, Jin Yang & Tianpei Hong. (2014) Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. American Journal of Physiology-Endocrinology and Metabolism 306:12, pages E1431-E1441.
Crossref
Crossref
Thomas Karagiannis, Panagiota Boura & Apostolos Tsapas. (2014) Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety 5:3, pages 138-146.
Crossref
Crossref
R. Boussageon, F. Gueyffier & C. Cornu. (2014) Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: What is the level of evidence?. Diabetes & Metabolism 40:3, pages 169-175.
Crossref
Crossref
Andrew J. Krentz & Marcus Hompesch. (2014) Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. Pharmaceutical Medicine 28:3, pages 109-117.
Crossref
Crossref
Shikhar Agarwal, Akhil Parashar & Venu Menon. (2014) Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. American Journal of Cardiovascular Drugs 14:3, pages 191-207.
Crossref
Crossref
Jeffrey W. Stephens, Akhila Mallipedhi & Stephen C. Bain. 2014. Managing Cardiovascular Complications in Diabetes. Managing Cardiovascular Complications in Diabetes
116
139
.
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Crossref
F. S. Angeli & R. P. Shannon. (2013) Incretin-based therapies: can we achieve glycemic control and cardioprotection?. Journal of Endocrinology 221:1, pages T17-T30.
Crossref
Crossref
L. Masmiquel. (2014) Efectos cardiovasculares y seguridad de los fármacos hipoglucemiantes: situación actual. SEMERGEN - Medicina de Familia 40:2, pages 80-88.
Crossref
Crossref
Steven E Kahn, Mark E Cooper & Stefano Del Prato. (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. The Lancet 383:9922, pages 1068-1083.
Crossref
Crossref
Greg L. Plosker. (2014) Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:2, pages 223-242.
Crossref
Crossref
Sandeep Dhindsa & Ishwarlal Jialal. (2014) Potential Anti-Atherosclerotic Effects of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus. Current Diabetes Reports 14:2.
Crossref
Crossref
J.P.A. Ioannidis, Y. Zhou, C.Q. Chang, S.D. Schully, M.J. Khoury & A.N. Freedman. (2014) Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Annals of Oncology 25:1, pages 16-23.
Crossref
Crossref
R.C.L. Page. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
763
787
.
Christine Berndt-Zipfel, Georg Michelson, Markus Dworak, Michael Mitry, Andrea Löffler, Andreas Pfützner & Thomas Forst. (2013) Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study. Cardiovascular Diabetology 12:1.
Crossref
Crossref
André J. Scheen. (2013) GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?. Annales d'Endocrinologie 74:5-6, pages 515-522.
Crossref
Crossref
David Kountz. (2013) The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups. Advances in Therapy 30:12, pages 1067-1085.
Crossref
Crossref
Angelo Pietro Femia, Laura Raimondi, Giulia Maglieri, Maura Lodovici, Edoardo Mannucci & Giovanna Caderni. (2013) Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. International Journal of Cancer 133:10, pages 2498-2503.
Crossref
Crossref
German Ramirez, Anthony D. Morrison & Polly A. Bittle. (2013) Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease. Endocrine Practice 19:6, pages 1025-1034.
Crossref
Crossref
Jaime A. Davidson. (2013) The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. Endocrine Practice 19:6, pages 1050-1061.
Crossref
Crossref
Satish K. GargAaron W. MichelsViral N. Shah. (2013) Use of Non-Insulin Therapies for Type 1 Diabetes. Diabetes Technology & Therapeutics 15:11, pages 901-908.
Crossref
Crossref
Bob Ryder, John McKnight, Andrew Blann, Ketan Dhatariya, Rob Gregory, Tony Robinson, Susannah Rowles, Patrick Sharp, Peter H Winocour & Chris Walton. (2013) ABCD position statement on GLP‐1 based therapies and pancreatic damage. Practical Diabetes 30:9, pages 388-391.
Crossref
Crossref
William B. White, Christopher P. Cannon, Simon R. Heller, Steven E. Nissen, Richard M. Bergenstal, George L. Bakris, Alfonso T. Perez, Penny R. Fleck, Cyrus R. Mehta, Stuart Kupfer, Craig Wilson, William C. Cushman & Faiez Zannad. (2013) Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine 369:14, pages 1327-1335.
Crossref
Crossref
M. Monami, S. Genovese & E. Mannucci. (2013) Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 15:10, pages 938-953.
Crossref
Crossref
Amita Singh, Robert Donnino, Howard Weintraub & Arthur Schwartzbard. (2013) Effect of Strict Glycemic Control in Patients With Diabetes Mellitus on Frequency of Macrovascular Events. The American Journal of Cardiology 112:7, pages 1033-1038.
Crossref
Crossref
Jeremy J Walker, Jeffrey A Johnson & Sarah H Wild. (2013) Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. The Lancet Diabetes & Endocrinology 1:2, pages 132-139.
Crossref
Crossref
Ozen Oz Gul, Nilufer Cinkilic, Cuma Bulent Gul, Soner Cander, Ozgur Vatan, Canan Ersoy, Dilek Yılmaz & Ercan Tuncel. (2013) Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 757:1, pages 31-35.
Crossref
Crossref
Timothy Bailey. (2013) Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm. The American Journal of Medicine 126:9, pages S10-S20.
Crossref
Crossref
Carlo Maria Rotella, Laura Pala & Edoardo Mannucci. (2013) Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future. International Journal of Endocrinology and Metabolism 11:3.
Crossref
Crossref
Guillermo E. Umpierrez & Luigi Meneghini. (2013) Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice. Endocrine Practice 19:4, pages 718-728.
Crossref
Crossref
Clifford J. Bailey. (2013) Interpreting Adverse Signals in Diabetes Drug Development Programs. Diabetes Care 36:7, pages 2098-2106.
Crossref
Crossref
Masato Kasuga, Kohjiro Ueki, Naoko Tajima, Mitsuhiko Noda, Ken Ohashi, Hiroshi Noto, Atsushi Goto, Wataru Ogawa, Ryuichi Sakai, Shoichiro Tsugane, Nobuyuki Hamajima, Hitoshi Nakagama, Kazuo Tajima, Kohei Miyazono & Kohzoh Imai. (2013)
Report of the
J
apan Diabetes Society/
J
apanese Cancer Association joint committee on diabetes and cancer
. Cancer Science 104:7, pages 965-976.
Crossref
Crossref
O. Mosenzon, I. Raz, B. M. Scirica, B. Hirshberg, C. I. Stahre, P. G. Steg, J. Davidson, P. Ohman, D. L. Price, B. Frederich, J. A. Udell, E. Braunwald & D. L. Bhatt. (2013) Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial. Diabetes/Metabolism Research and Reviews 29:5, pages 417-426.
Crossref
Crossref
Masato Kasuga, Kohjiro Ueki, Naoko Tajima, Mitsuhiko Noda, Ken Ohashi, Hiroshi Noto, Atsushi Goto, Wataru Ogawa, Ryuichi Sakai, Shoichiro Tsugane, Nobuyuki Hamajima, Hitoshi Nakagama, Kazuo Tajima, Kohei Miyazono & Kohzoh Imai. (2013) Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetology International 4:2, pages 81-96.
Crossref
Crossref
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman & Barry J. Goldstein. (2013) Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy 4:1, pages 119-145.
Crossref
Crossref
Mary Elizabeth Cox & Mark N. Feinglos. (2013) Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes. Current Diabetes Reports 13:3, pages 319-328.
Crossref
Crossref
Hiroshi Noto, Atsushi Goto, Tetsuro Tsujimoto, Keiichiro Osame & Mitsuhiko Noda. (2013) Latest insights into the risk of cancer in diabetes. Journal of Diabetes Investigation 4:3, pages 225-232.
Crossref
Crossref
Krzysztof Łabuzek, Michał Kozłowski, Dawid Szkudłapski, Patrycja Sikorska, Monika Kozłowska & Bogusław Okopień. (2013) Incretin-based therapies in the treatment of type 2 diabetes — More than meets the eye?. European Journal of Internal Medicine 24:3, pages 207-212.
Crossref
Crossref
Jens Juul Holst & Carolyn F. Deacon. (2013) Is there a place for incretin therapies in obesity and prediabetes?. Trends in Endocrinology & Metabolism 24:3, pages 145-152.
Crossref
Crossref
M. Monami, B. Ahrén, I. Dicembrini & E. Mannucci. (2012) Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 15:2, pages 112-120.
Crossref
Crossref
André J. Scheen. (2013) Cardiovascular effects of gliptins. Nature Reviews Cardiology 10:2, pages 73-84.
Crossref
Crossref
Sang Ah Lee. (2013) DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes. The Journal of Korean Diabetes 14:3, pages 128.
Crossref
Crossref
Nam Hoon KimSin Gon Kim. (2013) Comparison of DPP-4 Inhibitors. The Journal of Korean Diabetes 14:3, pages 111.
Crossref
Crossref
Hiroshi Noto, Atsushi Goto, Tetsuro Tsujimoto & Mitsuhiko Noda. (2013) 6. Diabetes and Cancer. Nihon Naika Gakkai Zasshi 102:4, pages 869-874.
Crossref
Crossref
Pegah Yousefzadeh & Xiangbing Wang. (2013) The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus. Journal of Diabetes Research 2013, pages 1-6.
Crossref
Crossref
Frank Pistrosch & Markolf Hanefeld. 2013. The Metabolic Syndrome. The Metabolic Syndrome
55
61
.
Zachary Bloomgarden. (2012) Diabetes treatment: The coming paradigm shift. Journal of Diabetes 4:4, pages 315-317.
Crossref
Crossref
Veerle Matheeussen, Wolfgang Jungraithmayr & Ingrid De Meester. (2012) Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacology & Therapeutics 136:3, pages 267-282.
Crossref
Crossref
O. Mosenzon & I. Raz. (2012) Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials. European Heart Journal Supplements 14:suppl B, pages B22-B29.
Crossref
Crossref
Michael H. Davidson. (2012) Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist. The American Journal of Cardiology 110:9, pages 43B-49B.
Crossref
Crossref
Bo Ahrén. (2012) Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes. Diabetes Management 2:5, pages 453-464.
Crossref
Crossref
Emma D. Deeks. (2012) Linagliptin. Drugs 72:13, pages 1793-1824.
Crossref
Crossref
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa & Paresh Dandona. (2012) Sitagliptin Exerts an Antinflammatory Action. The Journal of Clinical Endocrinology & Metabolism 97:9, pages 3333-3341.
Crossref
Crossref
Matteo Monami, Valentina Vitale, Maria Luisa Ambrosio, Nadia Bartoli, Giulia Toffanello, Benedetta Ragghianti, Francesca Monami, Niccolò Marchionni & Edoardo Mannucci. (2012) Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Advances in Therapy 29:9, pages 736-746.
Crossref
Crossref
J.M. Nagel. (2012) Beeinflussen Diabetestherapien das Krebsrisiko?Do antidiabetic therapies influence the risk for cancer?. Der Diabetologe 8:6, pages 463-472.
Crossref
Crossref
John R. Ussher & Daniel J. Drucker. (2012) Cardiovascular Biology of the Incretin System. Endocrine Reviews 33:2, pages 187-215.
Crossref
Crossref
Giuseppe Paolisso, Matteo Monami, Raffaele Marfella, Maria Rosaria Rizzo & Edoardo Mannucci. (2012) Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?. Advances in Therapy 29:3, pages 218-233.
Crossref
Crossref
Tomohiro Matsuhashi. (2012) Sitagliptin counteracts seasonal fluctuation of glycemic control. World Journal of Diabetes 3:6, pages 118.
Crossref
Crossref
Yuichiro Yamada. (2012) 1. Incretin-based Therapy: Present and Future. Nihon Naika Gakkai Zasshi 101:4, pages 1021-1026.
Crossref
Crossref
Lily P.H. Yang. (2012) Saxagliptin. Drugs 72:2, pages 229-248.
Crossref
Crossref
Matteo Monami, Caterina Lamanna, Carla Maria Desideri & Edoardo Mannucci. (2011) DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Advances in Therapy 29:1, pages 14-25.
Crossref
Crossref